Intraspinal grafting of fibroblasts genetically modified by recombinant adenoviruses

Neuroreport. 1998 Apr 20;9(6):1075-9. doi: 10.1097/00001756-199804200-00021.


Intracerebral or intraspinal grafting of genetically modified primary fibroblasts has been shown to enhance functional recovery in several models of CNS disease, including spinal cord injury. Most of these studies utilized retrovirus vectors. In this report, we describe in vitro conditions for genetically modifying primary fibroblasts with recombinant adenovirus vectors carrying the lacZ or green fluorescent protein (GFP) genes. As intraspinal allografts in animals immunosuppressed by cyclosporin A, the genetically modified cells survived and expressed the transgenes for at least 2 months. We conclude that recombinant adenovirus vectors are efficient and convenient tools for ex vivo gene therapy in the CNS.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae / genetics*
  • Animals
  • Animals, Genetically Modified
  • Cell Survival / physiology
  • DNA, Recombinant / genetics*
  • Female
  • Fibroblasts / transplantation
  • Genes, Reporter
  • Genetic Vectors*
  • Green Fluorescent Proteins
  • Image Processing, Computer-Assisted
  • Lac Operon*
  • Luminescent Proteins / genetics*
  • Rats
  • Rats, Sprague-Dawley
  • Spinal Cord Injuries / surgery*


  • DNA, Recombinant
  • Luminescent Proteins
  • Green Fluorescent Proteins